Study of Danicopan in Participants With Hepatic Impairment
Study Identifier:
ACH471-012
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Metabolism & Nutrition - Other
Study Drug
- Drug: Danicopan
Date
May 2018 - Sep 2018
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 75 Years
Requirements Information
Sex
Female & Male
Age
18 - 75 Years
Study Details
Medical Condition
- Metabolism & Nutrition - Other
Study Drug
- Drug: Danicopan
Date
May 2018 - Sep 2018
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 75 Years years
Requirements Information
Protocol Summary
The purpose of this study was to evaluate the safety, tolerability, and pharmacokinetics (PK) of ACH-0144471 (danicopan) in participants with hepatic impairment (HI) as compared to healthy matched participants.
Trial Locations
Location
Status
Location
Clinical Trial Site
Miami, Florida, United States, 33136
Status
N/A
Location
Clinical Trial Site
Orlando, Florida, United States, 32809
Status
N/A